K-numberK251533
Device nameRapid Obstructive Hydrocephalus, Rapid OH
ApplicantIschemaview, Inc.
Product codeQAS
Device classClass II
Decision dateSep 4, 2025
DecisionSubstantially Equivalent
Regulation892.2080
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Rapid OH is an AI/ML-based radiological computer-aided triage and notification software that analyzes non-enhanced CT head images to identify suspected obstructive hydrocephalus in adult patients. The device provides clinicians with priority notifications and compressed preview images for workflow prioritization, assisting with triage decisions while requiring clinicians to review full images per standard of care and not serving as a diagnostic device.

Technological characteristics

Rapid OH is a non-contrast CT processing module operating within the Rapid Platform that uses artificial intelligence and machine learning to analyze DICOM-formatted head images and generate priority notifications. It produces outputs including notifications, reports, and DICOM secondary capture series distributed via PACS, workstation, email, and mobile channels, with a notification time of approximately 30 seconds.

Test standards cited

EN ISO 14971:2019 (R2021) for risk management; IEC 62304:2006 (R2015) for software lifecycle processes; IEC 62366:2015 (R2020) for usability engineering; NEMA PS 3.1-3.20 for DICOM compliance; and 21 CFR 820.20 for verification and validation requirements.

Substantial equivalence argument

Rapid OH is substantially equivalent to Rapid SDH (K232436) because both devices share identical product code (QAS), regulation (21 CFR 892.2080), input requirements (non-contrast CT head images in DICOM format), technological approach (AI/ML-based triage and notification), contraindications structure, and output mechanisms. While Rapid OH targets obstructive hydrocephalus versus Rapid SDH's subdural hemorrhage, both function identically as workflow prioritization tools with equivalent performance architectures, achieving similar sensitivity/specificity profiles (89.5% sensitivity, 97.6% specificity) and employing the same notification and reporting infrastructure.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →